AbbVie vs Hitachi: Founders, CEOs and History
AbbVie was founded in 2013 by Abbott Laboratories (spin-off origin) and is led by Robert A. Michael. Hitachi was founded in 1910 by Namihei Odaira and is led by Toshiaki Tokunaga.
Company facts
Founders
AbbVie
Abbott Laboratories (spin-off origin)
Abbott Laboratories was AbbVie's corporate predecessor. AbbVie's official launch materials describe the company as formed in 2013 following separation from Abbott. Richard A.
Hitachi
Namihei Odaira
Hitachi possesses a historic, foundational founding story, rooted in the industrialization of early 20th-century Japan and driven by a nationalist obsession with technological independence.
CEOs and their tenures
AbbVie
- Richard A. Gonzalez2013–2024
Founding Chairman and Chief Executive Officer
Served as AbbVie's chief executive officer from its formation in 2013 through June 2024 and as executive chairman through June 2025.
Source - Robert A. Michael2024–present
Chairman and Chief Executive Officer
Became chief executive officer on July 1, 2024 and chairman on July 1, 2025. He previously led finance, commercial operations, and corporate strategy roles at AbbVie.
Source
Hitachi
- Toshiaki Higashihara2016–2022
Former President and Chief Executive Officer
Shifted Hitachi from a sprawling conglomerate toward infrastructure and digital businesses.
Source - Keiji Kojima2022–2025
Executive Chairman (CEO 2022-2025)
Finished much of the portfolio cleanup and handed over a more focused group to Tokunaga.
Source - Toshiaki Tokunaga2025–present
President and Chief Executive Officer
Brings an energy and rail background to the top job as Hitachi Energy and Hitachi Rail drive more of the group's growth.
Source
Timeline: AbbVie and Hitachi side by side
1910Hitachi
Founding and First Induction Motor
Namihei Odaira establishes the machinery repair shop that becomes Hitachi, and develops Japan's first 5-horsepower induction motor, establishing the foundation for the company's dominance in electrical engineering.
1932Hitachi
Expansion into Railway Technology
Hitachi begins manufacturing electric locomotives and rail signaling systems, establishing a deep, institutionalized relationship with the Japanese national railway network that would evolve into the modern Hitachi Rail division.
1959Hitachi
Entry into Computing and Electronics
Hitachi develops its first electronic computer, the HITAC, marking the company's strategic entry into the information technology sector and laying the groundwork for its future digital systems business.
2013AbbVie
AbbVie Launches as an Independent Company
AbbVie launched after Abbott Laboratories separated its research-based pharmaceutical business and began NYSE trading under ABBV.
2015AbbVie
Pharmacyclics Acquisition Completed
AbbVie completed its acquisition of Pharmacyclics, adding Imbruvica and expanding its hematologic oncology business.
2016Hitachi
Toshiaki Higashihara becomes CEO
Toshiaki Higashihara became CEO of Hitachi in 2016. Shifted Hitachi from a sprawling conglomerate toward infrastructure and digital businesses.
2019AbbVie
Skyrizi Receives Initial U.S. Approval
The FDA approved Skyrizi for adults with moderate to severe plaque psoriasis in April 2019.
2019AbbVie
Rinvoq Receives Initial U.S. Approval
The FDA approved Rinvoq for adults with moderate to severe rheumatoid arthritis in August 2019.
2020AbbVie
Allergan Acquisition Completed
AbbVie completed the Allergan acquisition, adding neuroscience, eye care, and Allergan Aesthetics products including Botox and Juvederm.
2020Hitachi
Acquisition of ABB's Power Grids Business
Hitachi executes the $11 billion acquisition of ABB's Power Grids business, renaming it Hitachi Energy and instantly establishing the company as the global leader in HVDC transmission and grid infrastructure.
2021Hitachi
Acquisition of GlobalLogic
The company acquires the global digital engineering firm GlobalLogic for $9.6 billion, instantly establishing Hitachi as a top-tier provider of advanced software and product design services for the automotive and telecommunications sectors.
2022Hitachi
Hitachi Construction Machinery Stake Sale
Hitachi sold a controlling stake in Hitachi Construction Machinery to Itochu and Japan Industrial Partners, part of its exit from cyclical listed subsidiaries.
2023AbbVie
U.S. Humira Biosimilar Competition Begins
Humira began facing U.S. biosimilar competition, and AbbVie reported a subsequent decline in Humira revenue.
2024AbbVie
ImmunoGen Acquisition Completed
AbbVie completed its acquisition of ImmunoGen, adding Elahere and antibody-drug conjugate programs.
2024AbbVie
Robert A. Michael Becomes CEO
Robert A. Michael succeeded Richard A. Gonzalez as chief executive officer effective July 1, 2024.
2024AbbVie
Cerevel Therapeutics Acquisition Completed
AbbVie completed its acquisition of Cerevel Therapeutics, adding clinical-stage neuroscience programs.
2024Hitachi
Acquired Thales Ground Transportation Systems
Hitachi acquired Thales Ground Transportation Systems. Hitachi Rail completed its ~$1.88 billion (EUR 1.66 billion) acquisition of Thales's Ground Transportation Systems business, its rail signalling division, expanding Hitachi Rail to 51 countries and shiftin…
2025AbbVie
Robert A. Michael Becomes Chairman
Robert A. Michael added the chairman role effective July 1, 2025, when Richard A. Gonzalez retired from the board.
2025AbbVie
FY2025 Revenue Reaches $61.160 Billion
AbbVie reported FY2025 net revenue of $61.160 billion and net income of $4.226 billion.
2025Hitachi
Toshiaki Tokunaga Becomes CEO
Toshiaki Tokunaga became President and CEO on April 1, 2025, succeeding Keiji Kojima, who became Executive Chairman.
2026AbbVie
Q1 2026 Revenue Reaches $15.002 Billion
AbbVie reported first-quarter 2026 net revenue of $15.002 billion, up 12.4 percent on a reported basis.
2026Hitachi
Record Results and Home Appliance Sale
Hitachi reported record FY2025 profit in April 2026 and agreed to sell 80.1% of its home appliance business to Nojima for about $737 million (¥110 billion).
Acquisitions
AbbVie
- ImmunoGen, Inc.2024$10.1B
- Cerevel Therapeutics2024$8.7B
- Allergan plc2020$63B
- Pharmacyclics, Inc.2015$21B
Hitachi
- Thales Ground Transportation Systems2024Undisclosed
- GlobalLogic2021Undisclosed
- ABB Power Grids2020Undisclosed
Questions about AbbVie vs Hitachi
Who is the CEO of AbbVie Inc. and Hitachi, Ltd.?
AbbVie Inc. is led by Robert A. Michael and Hitachi, Ltd. is led by Toshiaki Tokunaga. Both serve as the top executive responsible for the company's strategy, operations, and financial performance.
When was AbbVie Inc. founded vs Hitachi, Ltd.?
Hitachi, Ltd. was founded in 1910 — 103 years before AbbVie Inc., which was founded in 2013. Hitachi, Ltd.'s longer operating history gives it a deeper track record but also potentially more institutional inertia compared to the younger AbbVie Inc..
How many employees does AbbVie Inc. have compared to Hitachi, Ltd.?
AbbVie Inc. employs approximately 57,000 people, while Hitachi, Ltd. employs approximately 287,901. Hitachi, Ltd. has the larger workforce at 287,901 employees, compared to AbbVie Inc.'s 57,000. A higher headcount does not necessarily imply greater efficiency — it often reflects differences in business model (e.g., manufacturing vs. software).
Where are AbbVie Inc. and Hitachi, Ltd. headquartered?
AbbVie Inc. is headquartered in United States and Hitachi, Ltd. is headquartered in Japan. Their different home markets mean they may face different regulatory frameworks, tax regimes, and currency exposure.
Who founded AbbVie Inc. and Hitachi, Ltd.?
AbbVie Inc. was founded by Abbott Laboratories (spin-off origin). Hitachi, Ltd. was founded by Namihei Odaira.
Which company has a longer operating history — AbbVie Inc. or Hitachi, Ltd.?
Hitachi, Ltd. has been operating for approximately 116 years, making it the more established of the two companies. AbbVie Inc. has been in operation for around 13 years. A longer operating history often signals greater institutional resilience and brand recognition, though it can also mean slower adaptation to new market conditions.
Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the AbbVie vs Hitachi overview